Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00036842 · ClinicalTrials.gov registry record · Phase 2

Arsenic Trioxide in Treating Men With Germ Cell Cancer

A Phase 2 study of Testicular Germ Cell Tumor and Extragonadal Germ Cell Tumor, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase
20
Study locations

NCT00036842 is a Phase 2 study of Testicular Germ Cell Tumor and Extragonadal Germ Cell Tumor that has completed, run by SWOG Cancer Research Network. The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00036842, a Phase 2 study of Testicular Germ Cell Tumor and Extragonadal Germ Cell Tumor, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating men who have germ cell cancer that has not responded to previous treatment.

Conditions Studied

Testicular Germ Cell Tumor Extragonadal Germ Cell Tumor

Interventions

  • DRUG arsenic trioxide

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
  • Veterans Affairs Medical Center - West Los Angeles - Los Angeles
  • Veterans Affairs Outpatient Clinic - Martinez - Martinez
  • CCOP - Bay Area Tumor Institute - Oakland
  • Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center - Orange
  • University of California Davis Cancer Center - Sacramento
  • CCOP - Santa Rosa Memorial Hospital - Santa Rosa

Arizona

  • CCOP - Western Regional, Arizona - Phoenix
  • Veterans Affairs Medical Center - Phoenix (Carl T. Hayden) - Phoenix
  • Veterans Affairs Medical Center - Tucson - Tucson
  • Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
  • Veterans Affairs Medical Center - Little Rock - Little Rock

Colorado

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center - Aurora
  • Veterans Affairs Medical Center - Denver - Denver

Alabama

  • MBCCOP - Gulf Coast - Mobile

District of Columbia

  • MBCCOP - Howard University Cancer Center - Washington D.C.

Florida

  • Veterans Affairs Medical Center - Tampa (Haley) - Tampa

Georgia

  • CCOP - Atlanta Regional - Atlanta

Trial Details

FieldValue
Start Date 2002-04
Est. Completion 2007-06
Phase Phase 2

Sponsor

SWOG Cancer Research Network

270 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00036842

The ClinicalTrials.gov registry entry for NCT00036842 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Testicular Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which arsenic trioxide is the first listed.

NCT00036842 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00036842 about?

NCT00036842 is a clinical study titled "Arsenic Trioxide in Treating Men With Germ Cell Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating men who have germ cell cancer that has not responded to previous treatment.

What is the current status of trial NCT00036842?

This trial is currently completed. It is a Phase 2 study. The study started on 2002-04. Estimated completion is 2007-06.

What conditions does trial NCT00036842 study?

This clinical trial studies the following conditions: Testicular Germ Cell Tumor, Extragonadal Germ Cell Tumor.

What interventions are being tested in trial NCT00036842?

The interventions under investigation include: arsenic trioxide (DRUG).

Who is sponsoring clinical trial NCT00036842?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00036842 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Testicular Germ Cell Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Testicular Germ Cell Tumor

All registered trials for this condition

Extragonadal Germ Cell Tumor

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.